AI systems for mammography screening achieve 0.89 AUC and significantly reduce radiologist workloadAI tools show promise in detecting breast cancer during screening

European journal of radiology Published November 3, 2026 Study authors: Wulandari Putu Irma, Gandomkar Ziba, Rickard Mary, Hooshmand Sahand, Suleiman Mo'ayyad, Brennan Patr… PubMed ↗ DOI ↗ Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that AI systems show high AUC and significant workload reduction, but do not yet support replacing radiologists.

This meta-analysis synthesized data from 42 studies, including 39 retrospective and 3 prospective studies, to evaluate the diagnostic performance of FDA/CE-cleared AI systems in mammography screening. The analysis focused on standalone AI performance and integrated workflows compared to standard double reading.

Key findings include a standalone AI AUC of 0.89 (95% CI: 0.85-0.92) for digital mammography, with a sensitivity of 76.3% (95% CI: 66.2-84.2%) and a specificity of 89.6% (95% CI: 84.5-93.2%). In AI-integrated workflows, the analysis reported non-inferior cancer detection and a significant reduction in workload. When used as an additional reviewer, AI provided additional cancer detection with a minimal increase in recalls.

The authors noted that the risk of bias was frequently high, particularly regarding flow and timing. While AI systems show promising performance, the authors emphasize that prospective evidence supporting the complete replacement of radiologists is currently lacking. Clinical application is most supported in triage and independent or supporting reader models to reduce workload.

How this fits prior evidence

This meta-analysis addresses a gap in the technological integration of screening tools. While previous coverage focused on imaging protocols like MRI for specificity and the role of Periostin as a prognostic biomarker, this study focuses on the diagnostic performance and workflow efficiency of AI systems in mammography.

Finding breast cancer early is vital for treatment success. New research looked at how artificial intelligence (AI) performs when used during mammography screenings. The study looked at 42 different studies to see how these computer systems handled the task of identifying cancer compared to standard methods.

When used as a standalone tool, the AI showed a high accuracy rate for identifying potential issues. When integrated into a doctor's workflow, the AI was found to be just as effective as standard methods at detecting cancer. Importantly, using these systems significantly reduced the workload for medical staff while still finding cancer effectively.

While the results are promising, it is important to note that the evidence for replacing human doctors entirely is not yet complete. Some of the studies reviewed had a high risk of bias regarding how the data was collected. For now, the strongest evidence supports using AI to help sort cases or act as a second set of eyes to help doctors work more efficiently.

What this means for you:

AI tools can help radiologists find breast cancer and reduce their workload during mammogram screenings.

Common questions

How well does AI perform at finding breast cancer?

When used as a standalone tool for digital mammography, the AI showed a sensitivity of 76.3% and a specificity of 89.6%. These figures indicate how well the system identifies cancer while correctly identifying healthy tissue.

Does using AI make it harder for doctors to do their jobs?

No, the study found that using AI-integrated workflows actually led to a significant reduction in workload for staff. When used as an additional reviewer, the AI helped find more cancer with only a minimal increase in the number of patients called back for more tests.

Can AI completely replace a radiologist?

The evidence is not yet complete for replacing human doctors entirely. While the AI shows promising performance, the strongest evidence currently supports using it as a triage tool or as a supporting reader to help doctors manage their workload more effectively.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedNov 2026

PMID42561891

View Original Abstract ↓

OBJECTIVE: To evaluate the diagnostic performance of FDA/CE-cleared AI systems for mammography screening and assess their roles across clinical workflows. METHODS: A systematic search was conducted in Scopus, Embase, and PubMed for full-text articles published from January 2018 to July 2024 evaluating commercially available FDA/CE-cleared AI for breast cancer detection using digital mammography (DM) and/or digital breast tomosynthesis (DBT). Included studies specified the AI system and reported diagnostic performance metrics (e.g. sensitivity, specificity, AUC) and/or clinical impact (e.g. cancer detection rate [CDR], recall rate, workload). Study quality was assessed using a modified QUADAS-2 tool. A random-effects meta-analysis pooled standalone AI performance (sensitivity, specificity, and AUC); other workflow roles were synthesised narratively. RESULTS: In total, 42 studies were included (39 retrospective; 3 prospective): 33 evaluated DM, 6 DBT, and 3 both DM and DBT. Risk of bias was frequently high, particularly for flow and timing. In DM, pooled standalone AI AUC was 0.89 (95% CI: 0.85-0.92), with sensitivity of 76.3% (95% CI: 66.2-84.2%) and specificity of 89.6% (95% CI: 84.5-93.2%). Prospective evaluations of AI-integrated workflows, including triage and second-reader replacement, showed non-inferior cancer detection with significant workload reduction compared with standard double reading. A single prospective study of AI as an additional reviewer reported additional cancer detection with minimal increase in recalls. CONCLUSIONS: FDA/CE-cleared AI systems demonstrate promising diagnostic performance in breast screening. The strongest evidence supports workflow configurations that reduce radiologist workload, particularly triage and independent/supporting reader models, while prospective evidence supporting complete replacement of radiologists remains lacking.

AI systems for mammography screening achieve 0.89 AUC and significantly reduce radiologist workloadAI tools show promise in detecting breast cancer during screening

How this fits prior evidence

Common questions

Study Details

Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC

New data shows specific drug combinations improve triple-negative breast cancer outcomes

Clinical research that matters. Delivered to your inbox.

AI systems for mammography screening achieve 0.89 AUC and significantly reduce radiologist workloadAI tools show promise in detecting breast cancer during screening

How this fits prior evidence

Common questions

More on Breast Cancer

Study Details

Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC

New data shows specific drug combinations improve triple-negative breast cancer outcomes

Clinical research that matters. Delivered to your inbox.

Related in OB/GYN & Women's Health

From Other Specialties